Loading…
Employees: 2,831
Size Aarti Drugs (AARTIDRUGS.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $430M, the 905th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹446.75 on 6 Nov 2026.
Performance Over six months the shares gained 12.3%, against -13.2% for the median peer and 0.0% for the India market (cap-weighted) — 3rd highest of 20 in its peer set.
Growth Revenue grew 15.1% over the last twelve months (peer median +3.1%); the operating margin is 10.9% (peer median 2.4%).
Valuation It trades at 18.9× forward earnings against a peer median of 21.7× (3rd cheapest of 8).
Price implies For today's price to make sense, revenue must grow about 20% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is +16 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.0 points below its cost of capital (13.2% WACC).
Next results Next results expected around 27 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹28.5B | ₹25.6B | ₹23.8B | ₹25.2B | ₹27.2B |
| Revenue growth | — | +7% | -6% | -7% | — |
| Gross profit | ₹8.75B | ₹3.72B | ₹3.46B | ₹3.64B | ₹3.69B |
| EBITDA | ₹3.84B | ₹3.06B | ₹2.87B | ₹3.20B | ₹3.15B |
| Net income | ₹2.29B | ₹1.95B | ₹1.68B | ₹1.71B | ₹1.66B |
| Free cash flow | n/a | ₹491M | ₹462M | ₹1.04B | -₹661M |
| Capital expenditure | n/a | ₹1.73B | ₹1.77B | ₹2.26B | ₹1.65B |
| Total debt | ₹6.20B | ₹5.77B | ₹6.15B | ₹5.64B | ₹6.09B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AARTIDRUGS.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +7.0% | -11.7% | 3rd highest of 21 |
| 6-month return | +12.3% | -13.2% | 3rd highest of 20 |
| Distance from 52-week high | -16.3% | -33.9% | 3rd highest of 21 |
| Revenue growth (TTM) | +15.1% | +3.1% | 4th highest of 19 |
| Operating margin | 10.9% | 2.4% | 5th highest of 19 |
| Forward P/E | 18.9× | 21.7× | 3rd cheapest of 8 |
| Growth the price implies (Req g, 7 yrs) | 19.7% | 2.8% | 2nd most demanding of 8 |
| Growth delivered (Del g) | +3.5% | +12.1% | 2nd lowest of 8 |
| Hurdle (Req g minus delivered) | +16.3 pp | -8.7 pp | most demanding of 8 |
| ROIC minus cost of capital | -3.0 pp | -0.5 pp | 7th lowest of 16 |
| EV / EBITDA | 12.2× | 16.3× | 3rd cheapest of 9 |
| Net debt / EBITDA | 1.6× | 0.2× | 4th most indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Aarti Drugs AARTIDRUGS.NS | India | $430M | +12% | +15% | 11% | 18.9× | 19.7% | +3.5% |
| Beijing Centergate Technologies (Holding) 000931.SZ | China | $430M | -20% | -16% | 2% | 21.2× | 9.9% | +6.7% |
| BlossomHill Therapeutics BLSM | United States | $429M | n/a | n/a | n/a | n/a | n/a | n/a |
| Jiangsu Bioperfectus Technologies 688399.SS | China | $432M | -44% | -8% | -23% | n/a | n/a | n/a |
| Lifecome Biochemistry 002868.SZ | China | $428M | -51% | -24% | -6% | n/a | n/a | n/a |
| Phathom Pharmaceuticals PHAT | United States | $427M | -57% | +87% | -9% | 24.2× | n/a | n/a |
| Puma Biotechnology PBYI | United States | $426M | +10% | -3% | 13% | 21.7× | 2.8% | +0.3% |
| Dong-A Socio 000640.KS | South Korea | $425M | -11% | +10% | 7% | 7.6× | -8.8% | +12.8% |
| Synmosa Biopharma 4114.TWO | Taiwan | $442M | +2% | +11% | 11% | n/a | 6.5% | +15.3% |
| Relmada Therapeutics RLMD | United States | $416M | -47% | n/a | n/a | n/a | n/a | n/a |
| Assembly Biosciences ASMB | United States | $416M | -31% | +125% | -12% | n/a | n/a | n/a |
| Jiangxi Synergy Pharmaceutical 300636.SZ | China | $414M | -16% | -2% | 3% | 54.8× | n/a | n/a |
| RPG Life Sciences RPGLIFE.NS | India | $448M | +2% | +12% | 18% | n/a | n/a | n/a |
| Evolus EOLS | United States | $449M | +7% | +14% | -7% | 27.4× | n/a | n/a |
| Gansu Longshenrongfa Pharmaceutical Industry 300534.SZ | China | $450M | +4% | -21% | 8% | n/a | 23.7% | +28.2% |
| Shanghai Fudan Forward S&T 600624.SS | China | $450M | -4% | -14% | -34% | n/a | n/a | n/a |
| Anhui Sunhere Pharmaceutical Excipients 300452.SZ | China | $412M | -16% | +9% | 19% | 14.4× | -4.5% | +12.1% |
| Shaanxi Panlong Pharmaceutical 002864.SZ | China | $411M | -13% | -9% | 9% | n/a | -0.4% | +11.2% |
| Hansa Biopharma HNSA.ST | Sweden | $410M | +39% | -4% | -304% | n/a | n/a | n/a |
| Aquestive Therapeutics AQST | United States | $454M | -16% | +13% | -114% | n/a | n/a | n/a |
| Gufic Biosciences GUFICBIO.NS | India | $454M | +44% | +17% | 14% | n/a | n/a | n/a |